{
    "Trade/Device Name(s)": [
        "iHealth Align Gluco-Monitoring System (BG1)",
        "iHealth Wireless Smart Gluco-Monitoring System (BG5)"
    ],
    "Submitter Information": "Andon Health Co., Ltd.",
    "510(k) Number": "K170231",
    "Predicate Device Reference 510(k) Number(s)": [
        "K153278"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "NBW"
    ],
    "Summary Letter Date": "August 14, 2017",
    "Summary Letter Received Date": "August 16, 2017",
    "Submission Date": "September 14, 2017",
    "Regulation Number(s)": [
        "21 CFR 862.1345"
    ],
    "Regulation Name(s)": [
        "Glucose test system"
    ],
    "Analyte Class(es)": [
        "chemistry"
    ],
    "Analyte(s)": [
        "Glucose"
    ],
    "Specimen Type(s)": [
        "Fresh capillary whole blood"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [
        "iHealth Align Glucose meter (BG1)",
        "iHealth Wireless Glucose meter (BG5)",
        "iHealth Gluco-Smart App"
    ],
    "Method(s)/Technology(ies)": [
        "Electrochemical biosensor",
        "Capillary action",
        "Enzyme: glucose dehydrogenase"
    ],
    "Methodologies": [
        "Blood glucose measurement"
    ],
    "Submission Type(s)": [
        "System",
        "Meter",
        "App",
        "Test Strip",
        "Control Solution",
        "Lancet",
        "Lancing device"
    ],
    "Document Summary": "FDA 510(k) summary for iHealth Align and Wireless Smart Gluco-Monitoring Systems for self-monitoring of blood glucose in capillary whole blood using mobile app connectivity.",
    "Indications for Use Summary": "For quantitative measurement of glucose in fresh capillary whole blood from multiple sites for self-testing by people with diabetes at home, as an aid to monitor diabetes control; not for diagnosis, screening, or neonatal use.",
    "fda_folder": "Clinical Chemistry"
}